These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 1975039)
21. Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes. Nielsen KA; Hansen EL; Gille S Scand J Clin Lab Invest; 2007; 67(3):280-90. PubMed ID: 17454842 [TBL] [Abstract][Full Text] [Related]
22. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Lennard MS; Lewis RV; Brawn LA; Tucker GT; Ramsay LE; Jackson PR; Woods HF Br J Clin Pharmacol; 1989 Apr; 27(4):429-34. PubMed ID: 2719899 [TBL] [Abstract][Full Text] [Related]
23. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R; Broly F; Destée A; Libersa C Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190 [No Abstract] [Full Text] [Related]
24. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537 [TBL] [Abstract][Full Text] [Related]
25. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Hanioka N; Kimura S; Meyer UA; Gonzalez FJ Am J Hum Genet; 1990 Dec; 47(6):994-1001. PubMed ID: 1978565 [TBL] [Abstract][Full Text] [Related]
26. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
27. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Meier PJ; Mueller HK; Dick B; Meyer UA Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386 [TBL] [Abstract][Full Text] [Related]
28. Predicting debrisoquine phenotype. Heim M; Meyer UA Lancet; 1991 Feb; 337(8737):363. PubMed ID: 1671255 [No Abstract] [Full Text] [Related]
33. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663 [TBL] [Abstract][Full Text] [Related]
34. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]
35. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin. Lennard MS; McGourty JC; Silas JH Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891 [TBL] [Abstract][Full Text] [Related]
36. New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine. Chida M; Ariyoshi N; Yokoi T; Nemoto N; Inaba M; Kinoshita M; Kamataki T Pharmacogenetics; 2002 Nov; 12(8):659-62. PubMed ID: 12439227 [No Abstract] [Full Text] [Related]
37. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Ashforth EI; Palmer JL; Bye A; Bedding A Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461 [TBL] [Abstract][Full Text] [Related]
38. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380 [TBL] [Abstract][Full Text] [Related]
39. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians. Woolhouse NM Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761 [No Abstract] [Full Text] [Related]